Home

Phase II STTR

BrachyFoam is excited to announce the recent award of a Phase II STTR grant from the National Cancer Institute to support development and commercialization of a hydrogel-based strategy for vaginal packing during brachytherapy. Over the next two years, we will work with our team to move this technology forward to a medical product and clinical… Continue reading Phase II STTR

BrachyFoam President and Founder, Tim Showalter, MD featured in UVA Licensing & Ventures Group 2017 Annual Report

Faculty Profile: UVA Cancer Center Radiation Oncologist, Tim Showalter, MD In medicine, there can be a frustrating paradox where the most innovative forms of treatment are available for patients, but scientific advancements are not simultaneously advancing the tools used to deliver them. Tim Showalter, MD, a radiation oncologist at the UVA Cancer Center uses an… Continue reading BrachyFoam President and Founder, Tim Showalter, MD featured in UVA Licensing & Ventures Group 2017 Annual Report